EUVIMEDEUVIMED entdecken
Crossref

Distinct genetic alterations drive Cushing disease vs silent corticotroph adenomas

Ticiana Paes iD, Qilin Zhang, Clarice O Borges, Dipika R Mohan, Victor Vaz, Beatriz S Soares, Rona S Carroll, Ursula B Kaiser iD, Timothy R Smith, Wenya Linda Bi, David Meredith iD, Antonio M Lerario und 1 weitere

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Ticiana Paes und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Mass General Brigham, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: ACTH-Secreting Pituitary Adenoma, Adenoma, Pituitary ACTH Hypersecretion. Die Arbeit nennt 80 Literaturangaben. Gefördert von: Evergreen Award, Brigham and Women's Hospital, Evergreen Award, Brigham and Women’s Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Corticotroph adenomas (CA) include functioning tumors causing Cushing disease (CD) and silent corticotroph adenomas (SCA), which differ markedly in size, clinical presentation, and aggressiveness. The molecular basis for these differences remains incompletely understood.

Objective

To characterize genomic and transcriptomic alterations underlying the divergent clinical behavior of CD and SCA.

Methods

Thirty-eight tumors from 34 patients underwent whole-exome sequencing, copy-number variation (CNV) analysis, and mRNA sequencing. Molecular findings were integrated with clinical, radiological, and pathological data.

Results

USP8/USP48 mutations were present in 10 of 21 CD tumors (48%) and were associated with low CNV levels, minimal invasion, and favorable post-operative remission. In contrast, five of 13 SCAs harbored TP53/ATRX/DAXX mutations, all had markedly elevated CNV, and aggressive clinical features. Transcriptomic analysis identified an ATRX-FAM138A mRNA fusion, resulting in loss of ATRX expression in an aggressive tumor. Unsupervised transcriptome analyses defined four clusters. All USP8/USP48-mutant CD clustered together had low CNV and low recurrence rates. Cluster 2 consisted of a mixture of CD and SCA, with intermediate CNV and nonaggressive behavior. Cluster 3 included USP8-wildtype CD with heterogeneous yet generally nonaggressive courses. Cluster 4 represented high-CNV tumors enriched for TP53/ATRX/DAXX alterations, with the highest rates of radiological invasion, persistent disease, and recurrence or progression. Across the cohort, higher CNV was significantly associated with parameters of aggressiveness.

Conclusion

CA comprise distinct molecular subtypes. USP8/USP48-mutant CD represents a low-CNV, low-risk group, whereas tumors harboring TP53/ATRX/DAXX mutations exhibit high CNV and aggressive clinical behavior. CNV and mutation profiling may assist in postoperative risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ACTH-Secreting Pituitary AdenomaAdenomaPituitary ACTH HypersecretionHumansFemaleMaleMiddle AgedAdultUbiquitin ThiolesteraseMutationEndopeptidasesDNA Copy Number VariationsExome SequencingAgedEndosomal Sorting Complexes Required for Transport

Stichwörter der Autor:innen

Cushing diseasecorticotroph tumorssilent corticotroph tumorstranscriptomic sequencingwhole-exome sequencing

Substanzen

Ubiquitin ThiolesteraseEndopeptidasesUSP8 protein, humanEndosomal Sorting Complexes Required for Transport

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes and Metabolism, Mass General Brigham, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Internal Medicine, Roger Williams Medical Center, Providence, RI 02908, USA.
  • Department of Neurosurgery and National Center for Neurological Disorders, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
  • Division of Endocrinology, Metabolism & Lipid Research, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63108, USA.
  • Division of Endocrinology, Department of Medicine, Federal University of Minas Gerais, Minas Gerais 30130-100, Brazil.
  • Department of Neurosurgery, Mass General Brigham, Harvard Medical School, Boston, MA 02115, USA.

ORCID-Profile: Ticiana Paes, Ursula B Kaiser, David Meredith, Ana Paula Abreu

Förderung

  • Evergreen Award, Brigham and Women's Hospital
  • Evergreen Award, Brigham and Women’s Hospital

Zitieren

APA

Paes, T., Zhang, Q., Borges, C. O., Mohan, D. R., Vaz, V., Soares, B. S., Carroll, R. S., Kaiser, U. B., Smith, T. R., Bi, W. L., Meredith, D., Lerario, A. M., & Abreu, A. P. (2026). Distinct genetic alterations drive Cushing disease vs silent corticotroph adenomas. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag229

Vancouver

Paes T, Zhang Q, Borges CO, Mohan DR, Vaz V, Soares BS, et al. Distinct genetic alterations drive Cushing disease vs silent corticotroph adenomas. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag229

BibTeX
@article{Paes2026,
  author = {Paes, Ticiana and Zhang, Qilin and Borges, Clarice O and Mohan, Dipika R and Vaz, Victor and Soares, Beatriz S and Carroll, Rona S and Kaiser, Ursula B and Smith, Timothy R and Bi, Wenya Linda and Meredith, David and Lerario, Antonio M and Abreu, Ana Paula},
  title = {Distinct genetic alterations drive Cushing disease vs silent corticotroph adenomas},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag229}
}
Kostenlos starten →